BRIEF-Edwards Lifesciences Says PASCAL Tricuspid Repair System Meets Main Goal In Clasp II TR Study
Reuters2026/11/02 18:29Nov 2 (Reuters) - Edwards Lifesciences Corporation EW.N:
CLASP II TR TRIAL DEMONSTRATES SUPERIOR CLINICAL, QUALITY-OF-LIFE BENEFITS WITH EDWARDS PASCAL SYSTEM
EDWARDS LIFESCIENCES CORPORATION - PASCAL SYSTEM DEMONSTRATES SUPERIORITY IN CLASP II TR TRIAL AT SIX MONTHS
EDWARDS LIFESCIENCES CORPORATION - 80% OF PASCAL PATIENTS ACHIEVE ≤ MODERATE TR AT 1 YEAR VERSUS 30% CONTROL
Source text: ID:nBw9VZVLBa
Further company coverage: EW.N
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays raises S&P Global price target to $572
Zhipu dropped 9.1% in the past 24 hours
Jim Cramer Calls Ralph Lauren Stock Top Apparel Pick Before Thursday Earnings
Crypto prices
More
